A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins

Tarsus Pharmaceuticals (TARS) has initiated a Phase 2 trial for TP-05, an oral candidate for Lyme disease prevention, bringing fresh attention to the company. While the stock has seen a 4.9% return in the last 7 days, its 90-day return shows a 14.2% decline, though it boasts significant long-term returns. The article discusses whether Tarsus, with growing revenue and a loss-making income, is undervalued or if its future growth is already priced into its current share price of US$70.22.